ICOS (Bothell, WA) and Texas Biotec...

ICOS (Bothell, WA) and Texas Biotechnology's Houston, TX) 178-subject 12-week, double-blind, placebo-controlled, Phase 2b/3 STRIDE (Sitaxsentan To Relieve ImpaireD Exercise in Pulmonary Arterial Hypertension) trial demonstrated that the close attention drug has a reasonable risk/benefit profile. bring under rules with New York Heart Association (NHYA) class 2 3 and 4 pulmonary arterial hypertension were randomized to receive 100 mg or 300 mg of the consideration drug or placebo once a day. The primary endpoint was change in percent of predicted peak V[Osub2] Change in 6-minute walk distance was a